Abstract
Anaplastic lymphoma kinase (ALK) gene rearrangements define a distinct molecular subset of non-small-cell lung cancer that is highly responsive to treatment with the ALK inhibitor crizotinib. Recently, it has been recognized that the brain is a frequent site of relapse among ALK-positive patients treated with crizotinib. In this report, we expand on these observations and present a series of ALK-positive patients with two distinct forms of metastatic, central nervous system involvement: intramedullary spinal cord metastasis and leptomeningeal carcinomatosis.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anaplastic Lymphoma Kinase
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / pathology*
-
Female
-
Gene Rearrangement*
-
Humans
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics
-
Lung Neoplasms / pathology*
-
Male
-
Meningeal Carcinomatosis / drug therapy
-
Meningeal Carcinomatosis / genetics
-
Meningeal Carcinomatosis / secondary*
-
Neoplasm Staging
-
Prognosis
-
Receptor Protein-Tyrosine Kinases / genetics*
-
Spinal Neoplasms / drug therapy
-
Spinal Neoplasms / genetics
-
Spinal Neoplasms / secondary*
Substances
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases